An FDA approval could send one Canadian-listed stock flying, says Raymond James analysts Michael W. Freeman. In a research update to clients January 7, the analyst upgraded Medexus Pharmaceuticals (Medexus Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:MDP) from “Outpeform 2” to “Strong Buy 1”, while maintaining his one-year price target of $4.00 on the […]
Following a big financing, Raymond James analyst Michael W. Freeman has cut his price target, but still thinks Profound Medical Corp. (Profound Medical Corp. Stock Quote, Chart, News, Analysts, Financials TSX:PRN) is undervalued. On December 10, PRN announced it had closed a (YS) $40.25-million financing, funds earmarked to develop and commercialize its Tulsa-Pro system. The […]
Share
Tweet
Share